ThromboGenics and BioInvent Amending Long-Standing Monoclonal Antibody Development Agreement

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: ThromboGenics NV via GlobeNewswire